Trevi Therapeutics (TRVI)
(Real Time Quote from BATS)
$2.86 USD
-0.04 (-1.38%)
Updated Jul 17, 2024 11:20 AM ET
3-Hold of 5 3
D Value F Growth C Momentum F VGM
Price, Consensus and EPS Surprise
TRVI 2.86 -0.04(-1.38%)
Will TRVI be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for TRVI based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for TRVI
Trevi Therapeutics (TRVI) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
Why Trevi Therapeutics (TRVI) Stock Might be a Great Pick
TRVI: What are Zacks experts saying now?
Zacks Private Portfolio Services
Trevi Therapeutics, Inc. (TRVI) Upgraded to Strong Buy: Here's Why
Down -38.07% in 4 Weeks, Here's Why You Should You Buy the Dip in Trevi Therapeutics, Inc. (TRVI)
Trevi Therapeutics, Inc. (TRVI) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
Other News for TRVI
Trevi Therapeutics management to meet with Oppenheimer
Trevi Therapeutics to Participate in Upcoming Investor and Healthcare Events
Trevi Therapeutics initiated with bullish view at Rodman & Renshaw
12 Health Care Stocks Moving In Thursday's After-Market Session
Trevi Therapeutics, Inc. (TRVI) Q1 2024 Earnings Call Transcript